Study is Designed to Assess the Safety and Tolerability of AZD4547 at Increasing Doses in Patients With Advanced Tumours
Launched by ASTRAZENECA · Sep 16, 2009
Trial Information
Current as of July 21, 2025
Terminated
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Minimum life expectancy of 12 weeks
- • The presence of a solid, malignant tumour that is resistance to standard therapies or for which no standard therapies exist
- • In the expansion for the study patients must have a tumour at least 1cm in size that can be measure using a CT or MRI scan, and provide a tumour sample to the sponsor company for testing of FGFR1 and/or 2 amplification
- • Expansion, 5 groups of advanced cancer
- • Solid tumours,FGFR1 and/or FGFR2 gene amplified
- • Squamous NSCLC, FGFR1 gene low \& high amplified
- • Gastric adenocarcinoma, including the lower oesophagus/gastro-oesophageal junction, FGFR2 gene low \& high amplified
- • Aged at least 25 years
- Exclusion Criteria:
- • Treatment with any other chemotherapy, immunotherapy or anticancer agents within 3 weeks before the first dose of study
- • An inability to be able to take the study medication
- • A bad reaction to AZD4547 or any drugs similar to it in structure or class.
About Astrazeneca
AstraZeneca is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines across various therapeutic areas, including oncology, cardiovascular, respiratory, and autoimmune diseases. With a strong commitment to scientific research and patient-centric solutions, AstraZeneca leverages cutting-edge technology and a robust pipeline to address unmet medical needs. The company collaborates with healthcare professionals, academic institutions, and other organizations to advance clinical trials and deliver transformative therapies, aiming to improve health outcomes and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
Houston, Texas, United States
Nashville, Tennessee, United States
Aurora, Colorado, United States
Villejuif, , France
Frankfurt, , Germany
Manchester, , United Kingdom
Newcastle Upon Tyne, , United Kingdom
Napoli, , Italy
Wolverhampton, , United Kingdom
Edinburgh, , United Kingdom
Philadelphia, Pennsylvania, United States
New Haven, Connecticut, United States
Detroit, Michigan, United States
Stanford, California, United States
Freiburg, , Germany
Köln, , Germany
Amsterdam, , Netherlands
Valencia, , Spain
Glasgow, , United Kingdom
Rotterdam, , Netherlands
Rozzano, , Italy
Birmingham, , United Kingdom
Pierre Benite, , France
Badajoz, , Spain
Majadahonda, , Spain
London, , United Kingdom
Patients applied
Trial Officials
Fabrice André, Dr
Principal Investigator
Institut de cancérologie Gustave Roussy
Donal Landers, Dr
Study Director
AstraZeneca
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials